Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept

Introduction Pseudomyxoma peritonei (PMP) is a rare disease characterized by the progressive accumulation of mucinous ascites and peritoneal implants. The optimal treatment for PMP includes the association of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). For p...

Full description

Bibliographic Details
Main Authors: Olivia Sgarbura, Mohammed Al Hosni, Andrea Petruzziello, Rodrigo Figueroa, Lakhdar Khellaf, Marie-Hélène Pissas, Sébastien Carrère, Stephanie Nougaret, Frédéric Bibeau, François Quénet
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:International Journal of Hyperthermia
Subjects:
Online Access:http://dx.doi.org/10.1080/02656736.2020.1772511
id doaj-d15892c88977457f9133a71739f07e7c
record_format Article
spelling doaj-d15892c88977457f9133a71739f07e7c2021-08-09T15:50:02ZengTaylor & Francis GroupInternational Journal of Hyperthermia0265-67361464-51572020-01-0137158559110.1080/02656736.2020.17725111772511Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of conceptOlivia Sgarbura0Mohammed Al Hosni1Andrea Petruzziello2Rodrigo Figueroa3Lakhdar Khellaf4Marie-Hélène Pissas5Sébastien Carrère6Stephanie Nougaret7Frédéric Bibeau8François Quénet9Surgical Oncology Department, Montpellier Cancer Institute, University of MontpellierSurgical Oncology Division, Department of Surgery, Sultan Qaboos University HospitalMarcelino Champagnat HospitalSanatorio AllendeUniversity of Medicine Montpellier 2 Rue de l’École de MédecineSurgical Oncology Department, Montpellier Cancer Institute, University of MontpellierSurgical Oncology Department, Montpellier Cancer Institute, University of MontpellierUniversity of Medicine Montpellier 2 Rue de l’École de MédecinePathology Department, Caen University Hospital, University of Caen NormandySurgical Oncology Department, Montpellier Cancer Institute, University of MontpellierIntroduction Pseudomyxoma peritonei (PMP) is a rare disease characterized by the progressive accumulation of mucinous ascites and peritoneal implants. The optimal treatment for PMP includes the association of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). For patients with a large burdensome disease, the completeness of cytoreduction sometimes requires maximal effort surgery. The aim of this article is to provide proof of concept for two stage cytoreductive surgery (CRS) in this category of patients. Methods and materials A two stage CRS and HIPEC with oxaliplatin was proposed for patients with bulky PMP including important involvement of the serosal surfaces of the bowel or colon who had an impaired nutritional status. The residual disease at the end of the first stage was less than 5 mm of thickness on several implants. Clinical, surgical and histopathological variables were analyzed. Results All eight patients completed the two-stage strategy. Mortality was nil. One Clavien Dindo grade 3 event occurred in each stage. After a median follow up of 29.5 months, all patients were alive and free of recurrence. All of the patients had histopathological complete response on the specimens obtained from the residual sites during the second stage surgery. Conclusions Two-stage surgical strategy is feasible for bulky PMP patients and it is associated with little high-grade morbidity and enhanced visceral sparing.http://dx.doi.org/10.1080/02656736.2020.1772511pseudomyxoma peritoneicytoreductive surgeryhyperthermic intraperitoneal chemotherapytwo-stage surgeryoxaliplatin
collection DOAJ
language English
format Article
sources DOAJ
author Olivia Sgarbura
Mohammed Al Hosni
Andrea Petruzziello
Rodrigo Figueroa
Lakhdar Khellaf
Marie-Hélène Pissas
Sébastien Carrère
Stephanie Nougaret
Frédéric Bibeau
François Quénet
spellingShingle Olivia Sgarbura
Mohammed Al Hosni
Andrea Petruzziello
Rodrigo Figueroa
Lakhdar Khellaf
Marie-Hélène Pissas
Sébastien Carrère
Stephanie Nougaret
Frédéric Bibeau
François Quénet
Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept
International Journal of Hyperthermia
pseudomyxoma peritonei
cytoreductive surgery
hyperthermic intraperitoneal chemotherapy
two-stage surgery
oxaliplatin
author_facet Olivia Sgarbura
Mohammed Al Hosni
Andrea Petruzziello
Rodrigo Figueroa
Lakhdar Khellaf
Marie-Hélène Pissas
Sébastien Carrère
Stephanie Nougaret
Frédéric Bibeau
François Quénet
author_sort Olivia Sgarbura
title Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept
title_short Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept
title_full Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept
title_fullStr Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept
title_full_unstemmed Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept
title_sort complete pathologic response after two-stage cytoreductive surgery with hipec for bulky pseudomyxoma peritonei: proof of concept
publisher Taylor & Francis Group
series International Journal of Hyperthermia
issn 0265-6736
1464-5157
publishDate 2020-01-01
description Introduction Pseudomyxoma peritonei (PMP) is a rare disease characterized by the progressive accumulation of mucinous ascites and peritoneal implants. The optimal treatment for PMP includes the association of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). For patients with a large burdensome disease, the completeness of cytoreduction sometimes requires maximal effort surgery. The aim of this article is to provide proof of concept for two stage cytoreductive surgery (CRS) in this category of patients. Methods and materials A two stage CRS and HIPEC with oxaliplatin was proposed for patients with bulky PMP including important involvement of the serosal surfaces of the bowel or colon who had an impaired nutritional status. The residual disease at the end of the first stage was less than 5 mm of thickness on several implants. Clinical, surgical and histopathological variables were analyzed. Results All eight patients completed the two-stage strategy. Mortality was nil. One Clavien Dindo grade 3 event occurred in each stage. After a median follow up of 29.5 months, all patients were alive and free of recurrence. All of the patients had histopathological complete response on the specimens obtained from the residual sites during the second stage surgery. Conclusions Two-stage surgical strategy is feasible for bulky PMP patients and it is associated with little high-grade morbidity and enhanced visceral sparing.
topic pseudomyxoma peritonei
cytoreductive surgery
hyperthermic intraperitoneal chemotherapy
two-stage surgery
oxaliplatin
url http://dx.doi.org/10.1080/02656736.2020.1772511
work_keys_str_mv AT oliviasgarbura completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept
AT mohammedalhosni completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept
AT andreapetruzziello completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept
AT rodrigofigueroa completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept
AT lakhdarkhellaf completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept
AT mariehelenepissas completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept
AT sebastiencarrere completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept
AT stephanienougaret completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept
AT fredericbibeau completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept
AT francoisquenet completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept
_version_ 1721213820475539456